NeuroSense Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	5.71	7.14	2.51	0.39	0.34
Research & Development	7.59	6.42	3.08	2.5	0.9
Operating Expenses	13.3	13.55	5.59	2.89	1.24
Operating Income	-13.3	-13.55	-5.59	-2.89	-1.24
Interest Expense / Income	2.21	0.05	1.19	0	0.01
Other Expense / Income	-4.23	-1.26	-2.73	-0.06	-0.02
Pretax Income	-11.28	-12.34	-4.04	-2.83	-1.22
Net Income	-11.28	-12.34	-4.04	-2.83	-1.22
Shares Outstanding (Basic)	12	12	6	6	5
Shares Outstanding (Diluted)	-	12	6	6	5
Shares Change	8.34%	84.27%	13.12%	19.10%	-
EPS (Basic)	-0.83	-1.07	-0.65	-0.51	-0.26
EPS (Diluted)	-0.83	-1.07	-0.65	-0.51	-0.26
Free Cash Flow	-8.48	-7.66	-1.56	-0.7	-0.59
Free Cash Flow Per Share	-0.68	-0.67	-0.25	-0.13	-0.13
EBITDA	-8.97	-12.21	-2.85	-2.82	-1.22
Depreciation & Amortization	0.1	0.09	0	0	0
EBIT	-9.07	-12.3	-2.86	-2.83	-1.22

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).